Company intelligence / Profile preview
GAIA BioMedicine
- Ownership
- Private
- Development stage
- Phase 1
Overview
The company has 3 ongoing clinical trials. DLT evaluation of the monotherapy cohort for GAIA-102 in the clinical trial for pediatric patients with relapsed/refractory solid malignancies has been completed. Progress reports on safety and clinical efficacy of GAIA-102 against pediatric solid malignant tumors will be presented at the 66th Annual Meeting of the Japanese Society of Pediatric Hematology/Oncology. An interim report of the clinical trial for peritoneal dissemination (gastric/pancreatic cancer) will be presented at the European Society for Medical Oncology 2024.[1][5]
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyNK-like cell therapy
- Industry
- Biotech
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on GAIA BioMedicine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GAIA BioMedicine.